Gynecologic Oncology - Cervical Cancer | |
|---|---|
| Study Name | Principal Investigator |
| MK2870-020-00 – A Phase 3 Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20). Read more. |
Sharyn Lewin, MD |
Gynecologic Oncology - Endometrial Cancer | |
| Study Name | Principal Investigator |
| GOG-3039 – A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced,
Recurrent or Metastatic Endometroid Endometrial Cancer. Read more. |
Sharyn Lewin, MD |
| MK2870-005-03 – A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy (MK2870-005/ENGOT-en-23/GOG-3095). Read more. |
Sharyn Lewin, MD |
Gynecologic Oncology - Ovarian Cancer | |
| Study Name | Principal Investigator |
| FIRST – A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival. Read more. |
Sharyn Lewin, MD |
| IMGN853-0424 – A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-alpha Expression. Read more. |
Sharyn Lewin, MD |
| DS6000-109 – A Phase 2/3 Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Dose Optimization and Phase 3 Study of R-DXd versus Investigator’s Choice of Chemotherapy in Platinum resistant Ovarian Cancer). Read more. |
Sharyn Lewin, MD |
| IMGN853-0421 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with Fra-high recurrent platinum-sensitive epithelial ovarian, fallopian tube,or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). Read more. |
Sharyn Lewin, MD |
| GOG-3068 – A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary, Peritoneal, and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial – HOTT). Read more. |
Sharyn Lewin, MD |
| IMGN151-1001 – A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers. Read more. |
Sharyn Lewin, MD |
| GCT1184-02 – A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer. Read more. |
Sharyn Lewin, MD |
